Results 61 to 70 of about 2,399 (178)

Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia. [PDF]

Genes (Basel), 2023
Dlouha D, Blaha M, Huckova P, Lanska V, Hubacek JA, Blaha V.   +5 more
europepmc   +1 more source

LDL Apheresis and Lp (a) Apheresis: A Clinician's Perspective. [PDF]

Curr Atheroscler Rep, 2021
Kayikcioglu M.
europepmc   +1 more source

Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia1

Journal of Lipid Research, 2012
We measured oxidized phospholipids (OxPL), lipoprotein (a) [Lp(a)], and lipoprotein-associated phospholipase A2 (Lp-PLA2) pre- and postapheresis in 18 patients with familial hypercholesterolemia (FH) and with low(∼10 mg/dl; range 10–11 mg/dl ...
Kiyohito Arai, Alexina Orsoni, Ziad Mallat, Alain Tedgui, Joseph L. Witztum, Eric Bruckert, Alexandros D. Tselepis, M. John Chapman, Sotirios Tsimikas   +8 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-940, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Low-Density Lipoprotein Apheresis in Patients with Acute Kidney Injury Due to Minimal Change Disease Requiring Acute Renal Replacement Therapy

International Journal of Nephrology and Renovascular Disease, 2020
Kohsuke Terada, Koji Mugishima, Sayuri Kawasaki, Fumiaki Itagaki, Takehisa Yamada, Yukinao Sakai Department of Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanCorrespondence: Yukinao SakaiDepartment of Nephrology, Graduate ...
Terada K, Mugishima K, Kawasaki S, Itagaki F, Yamada T, Sakai Y   +5 more
doaj  

Abstracts of the 18th SCWD Conference, 11‐13 December 2025 in Rome/Italy

JCSM Communications, Volume 9, Issue 1, January/June 2026.
wiley   +1 more source

Outpatient monthly plasmapheresis with post-PLEX evinacumab in pediatric homozygous familial hypercholesterolemia: a case report on port access and immunoglobulin preservation

Frontiers in Pediatrics
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein (LDL) cholesterol levels, predisposing patients to early cardiovascular disease.
Guido Filler, Kambiz Norozi, Kambiz Norozi   +2 more
doaj   +1 more source

CLINICAL APPLICATION OF HELP-APHERESIS IN FEMALE PATIENT WITH FAMILIAL HYPERCHOLESTEROLEMIA

Фундаментальная и клиническая медицина, 2018
Cardiovascular diseases caused by atherosclerosis and its complications represent the leading cause of death in developed countries. The main risk factor of atherosclerosis development is dyslipidemia, in particular familial hypercholesterolemia (FH ...
OLGA L. Barbarash, NATALIA V. Fedorova, VASILIY V. Kashtalap, ROMAN A. Kornelyuk, OLESYA E. Astafurova, DMITRIY L. Shukevich, OLGA V. Gruzdeva   +6 more
doaj  

Long-term effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia: an observational case series

Orphanet Journal of Rare Diseases
Background We assessed long-term real-world effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia (HoFH). Methods Retrospective case series of six patients with HoFH treated with lomitapide in an Italian clinic.
Patrizia Suppressa, Chiara Coppola, Veronica Cocco, Sallyann O’Brien   +3 more
doaj   +1 more source

Discontinuation of LDL apheresis with evolocumab in an FH patient with a duplication of exon 2-6 in the LDLR gene. [PDF]

J Cardiol Cases, 2019
Nose D, Hori M, Miyamoto Y, Imaizumi S, Harada-Shiba M, Saku K, Miura SI.   +6 more
europepmc   +1 more source